Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

234 results about "Tocotrienol" patented technology

The vitamin E family comprise four tocotrienols (alpha, beta, gamma, delta) and four tocopherols (alpha, beta, gamma, delta). The critical chemical structural difference between tocotrienols and tocopherols is that tocotrienols have unsaturated isoprenoid side chains with three carbon-carbon double bonds versus saturated side chains for tocopherols (see Figure).

Microalgae-Based Beverages

The invention provides novel beverages and raw materials for the manufacture thereof, such beverage and raw materials containing microalgae of various species with varying components. Attributes of the microalgal biomass used in the invention include nutrition-providing materials such as carotenoids, dietary fiber, tocotrienols and tocopherols, and varying lipid compositions, particularly low levels of saturated lipids. Attributes of the microalgal biomass used in the invention include structural attributes such as improved mouth feel compared to alternative milk products such as soy milk and rice milk. The novel beverages provide delivery systems for high nutrition materials found in microalgae. The invention provides a new category of finished beverages based on microalgae (such as refrigerated and shelf stable liquids and emulsions) as well as compositions for augmenting properties of current beverages through inclusion of novel microalgae-based materials as ingredients.
Owner:TERRAVIA HLDG INC

Compositions and polymer composites prepared from the same

A composition including: a monomer mixture including a first monomer having at least two thiol groups at its terminal end and a second monomer having at least two carbon-carbon unsaturated bond-containing groups at its terminal end; and at least one additive selected from a zinc compound, an indium compound, ascorbic acid or a salt thereof, citric acid or a salt thereof, a tocopherol, and a tocotrienol.
Owner:SAMSUNG ELECTRONICS CO LTD

Method for producing purified tocotrienols and tocopherols using liquid chromatography

A method separating tocotrienols from tocopherols and the isomers thereof on a large-scale or commercially feasible basis. Separation is accomplished using reverse phase partition liquid chromatography. The chromatography column is prepared using a stationary phase comprising a hydrophobic or aromatic reverse phase chromatography media. The mobile phase consists of a solvent which is capable of solubilizing the crude stock, tocotrienols and tocopherols. The chromatography column containing the stationary and mobile phases is loaded with a crude feed stock and the tocotrienols, tocopherols and / or isomers thereof are eluted at a predetermined linear velocity.
Owner:ASAHI KASEI TECHNROM

Antioxidant compositions and methods thereto

The present invention provides a performance assay that measures the total antioxidant activity of a composition using oxygen uptake in contrast to prior art methods that measure antioxidant capacity by indirectly measuring degradation of a fluorescent compound by following the disappearance of fluorescence. Using the performance antioxidant assay of the present invention, an antioxidant composition having synergistic activity is provided by the present inventors that includes flavonoids such as the flavonol quercetin, mixed tocopherols or tocotrienols, grape skin extract, green tea extract and bush plum. The antioxidant activity of the present composition exceeds 6,000 micromoles Trolox equivalent units per gram using the present invention.
Owner:MANNATECH

Composition and method for treating cancer

A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.
Owner:MO HUANBIAO +3

Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure

ActiveUS20070099842A1Decreased anabolismIncreased catabolism of the macromoleculesCosmetic preparationsBiocideVitamin A RetinolSkin structure
The invention relates to compounds and to the cosmetically acceptable salts thereof, which correspond to general formula (I), wherein: R1 represents H, —C(O)—R6, —SO2—R6 or —C(O)—XR6; R2 and R4, independent of one another, represent (CH2)n—NH2 or (CH2)3—NHC(NH)NH2; n equals 1 4; R3 represents linear or branched C1-C4 alkyl that is optionally substituted by hydroxy; R5 and R6, independent of one another, represent hydrogen, optionally substituted (C1-C24) alkyl, optionally substituted C2-C24 alkenyl, optionally substituted phenyl, optionally substituted phenyl-C1-C4 alkyl or 9-fluorenyl-methyl; X represents oxygen (—O—) or —NH—; or XR5 with X=O also represents the esters of a-tocopherol, tocotrienol or retinol, with the provision that R1 and R5 do not represent hydrogen and X does not represent oxygen at the same time. The invention also relates to the production of the compounds of general formula (I) and to a cosmetically active composition that contains at least one compound of formula (I).
Owner:DSM IP ASSETS BV

Tocotrienol-containing powder, a process for preparing it and a tablet comprising compressed said powder into a tablet form

A tocotrienol-containing powder prepared by a process wherein an oil containing a tocotrienol is treated with a lecithin, a cellulose and an emulsifying agent in water to form an emulsion, a powder substance is mixed with the formed emulsion to form a suspension and then the formed suspension is spray-dried. The powder containing tocotrienol, which has excellent storage stability and free flowability, can be used in preparing a tablet which comprises the powder compressed into a tablet form.
Owner:FUJI CHEM IND CO LTD

Process for the production of tocotrienols

This invention relates to processes for the production of tocotrienol compounds from biological sources such as palm oil, cereals, grains, and grain oils. The tocotrienol products are recovered in high yields. These tocotrienols are useful as pharmaceuticals, in foodstuffs and as dietary supplements. These compositions are hypocholesterolemic, antioxidizing, antithrombotic, antiatherogenic, antiinflammatory and immunoregulatory in nature. Tocotrienols are known to lower the levels of low density lipoproteins in the bloodstream.
Owner:ARCHER DANIELS MIDLAND CO

Vitamin E tocotrienols inhibition of intracellularly obligate pathogen Chlamydia and methods of use

InactiveUS20060241174A1Reducing Chlamydia-induced blindnessLower blood pressureAntibacterial agentsBiocideControl cellLymph
This invention reveals the beneficial use of vitamin E tocotrienols for inhibition of chlamydial infections. Chlamydial infection levels in mouse macrophages treated with tocotrienol were decreased >50%, with concomitant aberrant pathogen development. The number of large and small inclusions in tocotrienol-versus-control cells was decreased 3-fold and 2-fold, respectively. When treated with delta tocotrienol, Chlamydia in human lymphocytes was inhibited by at least 2.6-fold in 1.5 days. Dietary delta tocotrienol inhibited Chlamydia infection and persistence in hypercholesterolemic patients with a corresponding drop in LDL. These studies demonstrate that tocotrienol lowers cholesterol, thus preventing or diminishing the cholesterol hijacking by Chlamydia obligatory for its infectivity and replication. Therefore, hypolipidemic agents used to treat cardiovascular diseases, metabolic syndrome, and diabetes are used as monotherapies, or in combination with tocotrienol to treat Chlamydia.
Owner:AMERICAN RIVER NUTRITION

Process for the production of alpha-tocotrienol and derivatives

ActiveUS20100105930A1Need of intensive and expensiveEconomical commercial processQuinone preparation by oxidationChemistrySource material
The invention discloses novel processes for production, enrichment and / or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.
Owner:PTC THERAPEUTICS INC

Device having hydration inhibitor

InactiveUS20060171984A1Reduce probabilityReduces restenosis in vasculatureBiocideHydroxy compound active ingredientsBeta-CaroteneDepressant
Medical devices comprising an interventional component for delivering multiple beneficial agents in which a hydration inhibitor controls release of at least one beneficial agent from the device. The hydration inhibitor is relatively less hydrophilic than the beneficial agent and preferably is a drug. Suitable beneficial agents include (I) dexamethasone, estradiol, anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipacdemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs, radiopaque markers, beta-carotene, tocopherols, tocotrienols, and antioxidants
Owner:ABBOTT LAB INC

Metallo-protein and tocotrienol (mp-t3) compositions and uses thereof

Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
Owner:NAIDU LP

Micronutrient phosphates as dietary and health supplements

InactiveUS20050009787A1Micronutrient compoundIncrease supplyBiocidePowder deliveryVitamin A RetinolMedicine
There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier.
Owner:VITAL HEALTH SCIENCES PTY LTD

Cytokine modulators and related method of use

ActiveUS20050058728A1Relieve and eliminate painRelieve and eliminate and tendernessBiocideNervous disorderDiseaseAstaxanthin
A composition for modulating cytokines to regulate an inflammatory or immunomodulatory response. The composition can include at least one of rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract, grape seed extract, resveratrol, Aframomum melegueta, boswellia serrata extract, boswellia forte, ipriflavone, tocotrienols, evening primrose oil, INM-176, borage oil, krill oil, at least one type of xanthophyll (e.g., astaxanthin), green coffee extract and ferulic acid. Specifically, a composition of the invention can include: rosehips and at least one of blackberry, blueberry, elderberry, and optionally krill oil; or rosehips, resveratrol and at least one of Aframomum melegueta and astaxanthin. Based on the cytokine modulation and cytokine response inhibition of the composition, it can be used to regulate an immunomodulatory and / or inflammatory response, and subsequently treat diseases and / or abnormal conditions associated with inflammatory response, for example, cardiovascular conditions, arthritis, osteoporosis and Alzheimer's disease.
Owner:ACCESS BUSINESS GRP INT LLC

Process for the recovery of a phytolipid composition

Disclosed is a process for the recovery of a phytolipid composition from a vegetable oil by-product. The phytolipid composition produced comprises squalene, phytosterols, mixed tocopherols and tocotrieneols, and vegetable wax and is useful as an emollient. The phytochemical composition may be applied directly to the skin to provide emolliency. Alternatively, the phytolipid composition may be formulated in various aqueous or anhydrous cosmetic compositions such as creams, lotions, gels, ointments, lip balms, sticks, or pencils for treatment of the skin and lips. The phytolipid composition also may be incorporated into foods, beverages, and nutraceuticals to provide health benefits.
Owner:EASTMAN CHEM CO

Livestock and poultry feed added with germinated brown rice

InactiveCN102396655ANo worries about chemical pollutionReduce manufacturing costAnimal feeding stuffPhytic acidPantothenic acid
The invention discloses livestock and poultry feed added with germinated brown rice, which is characterized in that 1.3-3.2g of germinated brown rice powder is added into livestock and poultry feed per kilogram, and the germinated brown rice per hectogram contains 500-600mg of gamma-aminobutyric acid (GABA). The gamma-aminobutyric acid is replaced with the germinated brown rice in the invention; and the germinated brown rice contains abundant energy substances, protein and lipid oxidation resistant substances, such as inositol, ferulic acid, tocopherol, tocotrienol, oryzanol, phytic acid and the like in addition to providing GABA and contains abundant mineral substance elements and vitamin, such as calcium, magnesium, ferrum, zinc, vitamin B1, vitamin B2, vitamin E, niacin, pantothenic acid and the like. The livestock and poultry feed is better for the growth and development of animals.
Owner:淮安市动物疫病预防控制中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products